Buy and tuck away18 Jun 2020 10:38
Pharmaceutical companies reinvest about 17% of all their revenue into the research and development (R&D) of new drugs. Smaller companies can spend up to half of their revenue funding new research.
To put this into perspective, the overall percentage spent on R&D in developing new products is just 1.3%. Even tech innovator Apple only spends about 3% of its sales to come up with the next groundbreaking product.
Considering that it costs on average about $4 billion – and up to $10 billion – to take a new drug from R&D to market, I see why Bill Gates is investing in the technology
Via SDGR...I own SDGR in USA...the UK investment community are v slow to recognise gems...PYC sounds good.
Software has been and will continue to be one of the most lucrative investment opportunities.
AI-driven software will transform the way drugs are discovered – an opportunity worth well over $250 billion in the years ahead.
In the case of Schrodinger, Schrodinger’s revenue grew 28.8% in 2019 to $85 million, and that’s just the tip of the iceberg. In the next four years, sales are expected to increase more than 4X to nearly $400 million in 2024. That equates to more than 30% annual growth over the next few years.
Profits are expected to grow even more impressively – 63% on average during each of the next four years. After losing $4.09 per share in 2019, the company is forecast to lose just $0.82 this year. By 2022, it should be profitable. And within four years, Schrodinger is expected to make about $2 per share.
Bill Gates was a very early investor in Schrodinger, and his foundation now owns nearly one-third of the entire company.
One statement from Bill Gates really jumped out at me as we battle the coronavirus pandemic. In April 2018, when discussing pandemics at an event, Gates said, “This preparation includes staging simulations, war games, and preparedness exercises so that we can better understand how diseases will spread and how to deal with responses such as quarantine and communications to minimize panic.”
He’s right. And I believe that healthcare breakthroughs like AI software that identifies potential new drugs quickly will allow scientists and doctors to respond so fast that pandemics become largely a thing of the past.
You may not have heard of the other big investor, billionaire hedge fund guru David Shaw, but he is well known in the investment world. He heads the D.E. Shaw hedge fund, and Fortune magazine referred to him as “the most intriguing and mysterious force on Wall Street.” Through his trust and personal account, he owns about 25% of Schrodinger.
Add it all up and two smart billionaires own about 58% of Schrodinger. Based on the past successes of these two computer whizzes, I am very comfortable joining them in investing in the future of AI and drug discovery. I own Shrodinger and I now own PYC.